This study is in progress, not accepting new patients

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

a study on Inflammatory Bowel Disease Ulcerative Colitis

Summary

Eligibility
for people ages 18-80 (full criteria)
Location
at UCSD
Dates
study started
study ends around

Description

Summary

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.

Official Title

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

Keywords

Ulcerative Colitis, Inflammatory Bowel Disease, Inflammatory Bowel Diseases, mirikizumab

Eligibility

You can join if…

Open to people ages 18-80

  • Participants from Study AMAC (NCT02589665) or AMBG (NCT03524092) who have had at least one study drug administration and have not had early termination of study drug.
  • Female participants must agree to contraception requirements.

You CAN'T join if...

  • Participants must not have developed a new condition, including cancer in the originator study.
  • Participants must not have any important infections including, but not limited to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during either originator study
  • Participants may not have received surgery for UC in the originator study or are likely to require surgery for treatment of UC during the study.
  • Participants must not have developed adenomatous polyps during the originator study that have not been removed prior to the start of this study.

Locations

  • University of California San Diego
    La Jolla 5363943 California 5332921 92037 United States
  • Clinical Applications Laboratories, Inc.
    San Diego 5391811 California 5332921 92103 United States
  • California Medical Research Associates
    Northridge 5377985 California 5332921 91324 United States
  • Care Access - Berkeley
    Berkeley 5327684 California 5332921 94705 United States
  • InSite Digestive Health Care
    Arcadia 5324477 California 5332921 91006 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
ID
NCT03519945
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 1063 study participants
Last Updated